Article ; Online: Generation of a GPR146 knockout human induced pluripotent stem cell line (ITXi001-A-1).
2022 Volume 60, Page(s) 102721
Abstract: Dyslipidemia is a key modifiable causal risk factor involved in the development of atherosclerotic cardiovascular disease. Recently, the G protein-coupled receptor 146 (GPR146), a member of the G-coupled protein receptors' family, has been shown to be a ... ...
Abstract | Dyslipidemia is a key modifiable causal risk factor involved in the development of atherosclerotic cardiovascular disease. Recently, the G protein-coupled receptor 146 (GPR146), a member of the G-coupled protein receptors' family, has been shown to be a regulator of plasma cholesterol. Inhibition of hepatic GPR146 in mice displays protective effect against both hypercholesterolemia and atherosclerosis. Here, we characterize a genetically engineered human induced pluripotent stem cell (hiPSC) model invalidated for GPR146 (ITXi001-A-1) using CRISPR-Cas9 editing technology. Differentiation of ITXi001-A-1 towards hepatic fate will provide a suitable model for deciphering the molecular mechanisms sustaining the beneficial metabolic effects of GPR146 inhibition. |
---|---|
MeSH term(s) | Animals ; CRISPR-Cas Systems/genetics ; Cell Differentiation ; Humans ; Induced Pluripotent Stem Cells/metabolism ; Liver ; Mice |
Language | English |
Publishing date | 2022-02-25 |
Publishing country | England |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2393143-7 |
ISSN | 1876-7753 ; 1873-5061 |
ISSN (online) | 1876-7753 |
ISSN | 1873-5061 |
DOI | 10.1016/j.scr.2022.102721 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.